Dimerization: a versatile switch for oncogenesis
- 15 August 2004
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 104 (4) , 919-922
- https://doi.org/10.1182/blood-2004-03-0992
Abstract
Forced dimerization or oligomerization has emerged as a powerful mechanism for unleashing the oncogenic properties of chimeric transcription factors in acute leukemias. Fusion of transcriptional regulators with a variety of heterologous partner proteins as a consequence of chromosomal rearrangements induces inappropriate self-association, leading to aberrant transcriptional properties and leukemogenesis. Forced dimerization/oligomerization may alter the association of a DNA-binding protein for its transcriptional cofactors, or the dimerization motifs themselves may constitutively recruit transcriptional effector molecules. Oligomerized chimeras may also sequester essential partners or cofactors to exert dominant-negative effects on target gene expression. A key mechanistic feature, and one with major clinical implications, is the nature of the transcriptional cofactors that are recruited by the dimerized oncoprotein. Chimeric RARα and acute myeloid leukemia 1 (AML1) proteins induce constitutive repression after the recruitment of corepressors, whereas inappropriate maintenance of target gene expression by mixed-lineage leukemia (MLL) chimeras may result from the recruitment of coactivators or the basal transcriptional machinery. Molecular therapies directed at enzymatic activities of the aberrantly recruited cofactors, or antagonism of dimerization itself, represent promising avenues of current and future investigation.Keywords
This publication has 40 references indexed in Scilit:
- Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9Blood, 2004
- Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemiaBlood, 2004
- Histone deacetylase inhibitors in cancer therapyCancer Cell, 2003
- Essential role for the dimerization domain of NuMA-RARα in its oncogenic activities and localization to NuMA sites within the nucleusOncogene, 2003
- Transcriptional activation is a key function encoded by MLL fusion partnersLeukemia, 2003
- Common mechanism for oncogenic activation of MLL by forkhead family proteinsBlood, 2003
- The impact of differential binding of wild-type RARα, PML-, PLZF- and NPM-RARα fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemiaLeukemia, 2000
- The TEL-AML1 Fusion Accompanied by Loss of the Untranslocated TEL Allele in B-Precursor Acute Lymphoblastic Leukaemia of ChildhoodLeukemia & Lymphoma, 2000
- Formation of PML/RARα high molecular weight nuclear complexes through the PML coiled-coil region is essential for the PML/RARα-mediated retinoic acid responseOncogene, 1999
- Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APLNature Genetics, 1998